---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-037948"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2024-09-24T23:59:59+00:00"
generated_at: "2026-05-31T02:11:42.598098+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics enters 5-year MSA with Charles River Labs for development and manufacturing services

## Summary
- Master Services Agreement with Charles River Laboratories effective September 19, 2024.
- Term expires September 19, 2029; services and fees set via future Statements of Work.
- Covers development and CDMO services including cell/gene therapy products.
- Either party can terminate on 90 days' notice; material breach cure period also 90 days.
- Standard confidentiality, IP, warranty, and indemnity terms; financial caps redacted.

## SEC filing metadata
- accession: 0001493152-24-037948
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2024-09-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000149315224037948/0001493152-24-037948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000149315224037948/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-037948
- JSON: https://secwatch.observer/filing/0001493152-24-037948.json
- Plain text: https://secwatch.observer/filing/0001493152-24-037948.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.